Ascendis Pharma A/S
ASND scores 75.7 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
No material penalties applied. ASND ranks #30 based on its factor profile and ML signal alignment.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| ASND | 75.7 | 16.6 | 98.0% | -31.7% | $13.3B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $20.1B |
| GMAB | 85.5 | 13.1 | 22.8% | 36.4% | $18.5B |
| CPRX | 82.2 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $126.0B |
| NBIX | 74.7 | 26.5 | 21.4% | 16.7% | $12.5B |
| ALKS | 74.6 | 16.5 | -6.4% | 23.9% | $5.5B |
| AMGN | 73.8 | 26.0 | 10.0% | 21.0% | $199.0B |
| ARGX | 73.6 | 35.1 | 78.6% | 38.0% | $50.9B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.7 | 19.4 | 1.0% | 31.4% | $84.9B |
| ISRG | 72.3 | 61.7 | 20.5% | 28.4% | $172.5B |
| EXEL | 71.9 | 15.1 | 7.0% | 33.7% | $11.7B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $8.0B |
| HALO | 70.2 | 16.8 | 22.4% | 43.7% | $9.3B |
| BMRN | 69.7 | 22.3 | 18.0% | 15.0% | $11.5B |
| Sector Average | 37.1 | 252.3 | 161.5% | -3292.7% | â |
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 Ă/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $245M | $214M | $158M | $101M |
| Gross Profit | $218M | $191M | $127M | $83M |
| Operating Income | $10M | $11M | $-53M | $-104M |
| Net Income | $-33M | $-61M | $-39M | $-95M |
| EPS (Diluted) | $-0.54 | $-1.00 | $-0.82 | $-1.58 |
| Gross Margin | 88.9% | 89.5% | 80.1% | 82.6% |
| Operating Margin | 4.0% | 5.1% | -33.5% | -103.2% |
| Net Margin | -13.6% | -28.5% | -24.6% | -93.7% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $109.36 | $178.71 | 48.1% | Wide |
| 2022 | $61.58 | $137.40 | 76.2% | Wide |
| 2023 | $64.33 | $129.43 | 67.2% | Wide |
| 2024 | $111.09 | $161.00 | 36.7% | Wide |
| 2025 | $118.03 | $229.94 | 64.3% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.